Issta sets NIS 315m. 5-year plan

As the first stage of the plan, Issta said it bought Mabat Touring Services for an undisclosed amount.

By AVI KRAWITZ
February 13, 2006 08:00
issta logo 88

issta logo 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Tour operator Issta Lines presented a strategic plan on Sunday to invest NIS 315 million in the company over the next five years. As the first stage of the plan, Issta said it bought Mabat Touring Services for an undisclosed amount. The company said it plans to grow sales to NIS 2.5 billion from NIS 1.5b. over the period and the company's board of directors authorized an offering of 1.1 million shares to finance the program. Ahishay Gal, CEO, said Issta intends to bring about growth by purchasing new operations, creating new income sources in the hotel and tourism sector, and entering new areas such as inbound tourism.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS